FDA Flags Potential NAION Vision‑Loss Risk with GLP‑1 RA Medications – Labeling Update Required Across the Drug Class
The U.S. Food and Drug Administration (FDA) announced it is informing patients and health care providers of a potential increased risk of non‑arteritic anterior ischemic optic neuropathy (NAION) associated with…
Immunochina’s IM19 Wins NMPA Approval – First Fully In‑House CD19 CAR‑T Cell Therapy for Relapsed or Refractory Large B‑Cell Lymphoma in China
Immunochina Pharmaceuticals, a Beijing‑based biotech, announced that its first fully in‑house developed, CD19‑targeted autologous CAR‑T cell therapy, IM19 CAR‑T Cell (development code: IM19), has been approved for marketing by China's National Medical Products Administration (NMPA) for the treatment of adult…
Where biopharma's biggest deals take shape!
Your front-row seat to the deals reshaping the pharmaceutical landscape — mergers and acquisitions, licensing agreements, venture investments, and strategic partnerships. We track every major transaction, from blockbuster M&As to early-stage funding rounds, breaking down what each deal means for the companies, the pipeline, and the market.
Charles River to Acquire Frontage’s Bioanalysis and DMPK Operations for ~$470 Million – Expanding Early-Phase Laboratory Footprint in Exton, Pennsylvania
Charles River Laboratories International, Inc. (NYSE: CRL) announced that it will acquire the bioanalysis and DMPK (drug metabolism and pharmacokinetics) operations of Frontage Holdings Corporation (HKG: 1521), based in Exton,…
